Urine Drug Testing is essential for the effective monitoring compliance of pain medication. This testing can identify discrepancies between prescribed medications and patient compliance with treatment protocols. It plays a critical role in detecting potential risks associated with misuse, diversion, or the presence of illicit substances. Urine toxicology tests are typically administered prior to initiating chronic opioid therapy and periodically thereafter to ensure ongoing compliance. Healthcare providers are advised to consult the CDC’s Prescription Drug Monitoring Programs (PDMPs) when commencing opioid therapy for acute, subacute, or chronic pain, and at regular intervals during the continuation of opioid therapy. We offer standard urine drugs of abuse panels and comprehensive urine drug tests designed to cater to common requirements for pain medication monitoring. If your required analytes are not included in these two panels, you may request a customized panel for specific confirmation testing.

Urine Drug Testing primarily detects the presence of drugs or their metabolites and does not necessarily indicate the source, dosage, or route of administration. A positive result signifies that a drug or its metabolites were identified in the specimen (urine or saliva). Conversely, a negative result indicates that the drug was either not detected in the submitted specimen (urine or saliva) or was below the detection threshold.